Herceptin for Pre-Menopausal Women
Dear OncoLink "Ask The Experts,"
Kevin Fox, MD Assistant Director, Clinical Affairs and Associate Professor of Hematology/Oncology at the Abramson Cancer Center of the University of Pennsylvania responds:
Recommending for or against herceptin has nothing to do with the patient age or menopausal status. The recommendations regarding herceptin are based on the biopsy report that specifically evaluates a marker called HER-2/nue. Patients that have over-expression of this marker are candidates for herceptin therapy. It has thus far been used in patients with metastatic breast cancer and high risk locally advanced breast cancer. There are ongoing studies evaluating the best combination of herceptin with chemotherapy and the appropriate timing of administration. The safety and effectiveness of herceptin has not been evaluated in patients as treatment for "early stage" breast cancer. This is part of a current research trial.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania